TSVT Logo

2seventy bio, Inc. (TSVT) 

NASDAQ
Market Cap
$161.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
83 of 960
Rank in Industry
63 of 550

Largest Insider Buys in Sector

TSVT Stock Price History Chart

TSVT Stock Performance

About 2seventy bio, Inc.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Insider Activity of 2seventy bio, Inc.

Over the last 12 months, insiders at 2seventy bio, Inc. have bought $4.1M and sold $594,035 worth of 2seventy bio, Inc. stock.

On average, over the past 5 years, insiders at 2seventy bio, Inc. have bought $5.1M and sold $431,437 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Casdin Capital, LLC (director) — $16.41M.

The last purchase of 40,000 shares for transaction amount of $203,992 was made by Casdin Capital, LLC (director) on 2024‑03‑26.

List of Insider Buy and Sell Transactions, 2seventy bio, Inc.

2024-12-13SaleSee Remarks
2,287
0.0044%
$3.23$7,393-1.83%
2024-11-18Saledirector
3,900
0.0076%
$3.38$13,182-8.88%
2024-10-03SaleChief Financial Officer
1,230
0.0023%
$4.65$5,718-11.47%
2024-10-03SaleSee Remarks
679
0.0013%
$4.65$3,157-11.47%
2024-08-14SaleSee Remarks
7,816
0.0156%
$4.32$33,7600.00%
2024-08-05SaleChief Financial Officer
13
<0.0001%
$3.98$52+12.72%
2024-07-02SaleChief Financial Officer
12
<0.0001%
$4.02$480.00%
2024-07-02SaleSee Remarks
14
<0.0001%
$4.02$560.00%
2024-06-03SaleChief Financial Officer
1,167
0.0023%
$4.18$4,881+6.22%
2024-06-03SaleSee Remarks
649
0.0013%
$4.18$2,714+6.22%
2024-05-03SaleSee Remarks
15
<0.0001%
$4.91$74-6.53%
2024-03-26Purchasedirector
40,000
0.0812%
$5.10$203,992-8.27%
2024-03-25Purchasedirector
330,000
0.6747%
$5.07$1.67M-7.14%
2024-03-22Purchasedirector
147,377
0.2903%
$5.12$754,069-11.21%
2024-03-21Purchasedirector
300,000
0.5822%
$4.90$1.47M-8.98%
2024-01-05SalePresident and CEO
1,554
0.003%
$3.75$5,833+19.17%
2024-01-05SaleChief Scientific Officer
795
0.0015%
$3.75$2,984+19.17%
2024-01-05SaleChief Operating Officer
1,380
0.0027%
$3.75$5,180+19.17%
2024-01-03SalePresident and CEO
72,312
0.143%
$3.87$279,739+18.24%
2024-01-03SaleChief Scientific Officer
25,613
0.0506%
$3.87$99,084+18.24%

Insider Historical Profitability

<0.0001%
Casdin Capital, LLCdirector
2000000
3.8768%
$3.1440
Leschly NickPresident and CEO
1085476
2.1041%
$3.14110<0.0001%
Kynam Capital Management, LP10 percent owner
5953825
11.541%
$3.1420
Kynam Global Healthcare Master Fund, LP10 percent owner
5953825
11.541%
$3.1410

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Kynam Capital Management Lp$31.85M11.585.95M0%+$00.4
Morgan Stanley$23.31M8.484.36M-10.02%-$2.6M<0.01
Goldman Sachs$22.59M8.214.22M-6.37%-$1.54M<0.01
BlackRock$20.89M7.63.91M-0.16%-$33,806.65<0.0001
The Vanguard Group$19.96M7.263.73M-6.38%-$1.36M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.